Revive RX Pharmacy (Revive RX LLC), Houston, TX

Is Revive RX Pharmacy (Revive RX LLC) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Revive RX Pharmacy (Revive RX LLC) hold a Texas pharmacy license?

The Texas State Board of Pharmacy lists license 32011 for REVIVE RX, HOUSTON, status Active, as of Nov 15, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 7213 for Revive Rx Pharmacy, Houston, TX, status Active and license OSP 6854 for Revive Rx, Houston, TX, status Expired, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054021433 for REVIVE RX LLC, HOUSTON, TX, status ACTIVE, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0003752 for REVIVE RX, HOUSTON, TX, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0002513 for Revive Rx LLC, HOUSTON, TX, status Active, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301012456 for Revive Rx, LLC, Houston, TX, status Active, as of Nov 10, 2026.

Has Revive RX Pharmacy (Revive RX LLC) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Sep 22, 2025), 1 untitled letter (Jun 30, 2023) and 1 FMD-145 letter (Jan 22, 2025) for Revive RX Pharmacy (Revive RX LLC). State board actions: the Texas State Board of Pharmacy file dated Nov 15, 2026 marks prior disciplinary orders on license 32011 (column DISP ACTN, value Y); the orders themselves are on the board’s license lookup and are not copied here.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Revive RX LLC; Revive RX Pharmacy
Location
Houston, TX
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
4
Warning letters on FDA’s actions page
1
Latest action on that page
Mar 27, 2026
FDA Data Dashboard inspections
3 inspections: 2 OAI, 1 VAI; 4 published Form 483s
Form 483 text on this page
2 Form 483s, 12 observations
State board records
License found: 32011, Active

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Revive RX LLC, dba Revive RX Pharmacy, a 503A facility, with 7 dated actions.

Document
Mar 27, 2026Form 483483 Issued 3/27/2026fda.gov
Sep 22, 2025Warning letterWarning Letter Issued 09/22/2025fda.gov
Feb 7, 2025Form 483483 Issued 02/07/2025fda.gov
Jan 22, 2025FMD-145 letterFMD-145 Letter Issued 01/22/2025Not linked by FDA
Jun 30, 2023Untitled letterUntitled Letter Issued 06/30/2023FDA copy (archived)
May 4, 2022Form 483483 Issued 05/04/2022FDA copy (archived)
Aug 6, 2021Form 483483 Issued 08/06/2021FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Revive Rx LLC, Houston, TX (FEI number 3016710945), matched to this page by exact name, city and state. It lists 3 inspections: 2 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Feb 7, 2025Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30167109451261213
May 4, 2022Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30167109451168666
Aug 6, 2021Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30167109451149791

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 12 numbered observations in all, across 2 inspections ending Feb 7, 2025 to Mar 27, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Mar 9, 2026 to Mar 27, 2026: 5 observations

Firm on the cover
Revive Rx LLC dba Revive Rx Pharmacy, 3831 Golf Dr Ste A, Houston, TX 77018-5218
FEI number
3016710945
Establishment type on the cover
Producer of Sterile and Non-Sterile Drugs
FDA district office on the cover
19701 Fairchild Irvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Microbial contamination was present in the ISO 5 area and areas adjacent to production areas.

Specifically,

A. Your environmental monitoring data shows persistent and repeated recovery of microorganisms, including mold and spore-forming bacteria, in both ISO Class 5 and ISO 7 classified areas. Recoveries in ISO 5 areas:

4 • 3/5/2025: 1 CFU Gram-positive rods (not identified) recovered post-batch in Hood <Redacted B4> • 4/3/2025: 1 CFU Gram-positive rods (not identified) recovered post-batch in Hood <Redacted B4>

• 4/8/2025: 1 CFU Gram-positive rods (not identified) recovered post-batch in Hood <Redacted B4>

• 4/8/2025: 1 CFU Gram-positive rods (not identified) recovered post-batch in Hood <Redacted B4>

4 • 4/29/2025: 1 CFU (not stained, not identified) recovered post-batch in Hood <Redacted B4> • 5/12/2025: 1 CFU (not stained, not identified) recovered post-batch in Hood <Redacted B4>

,; 7/10/2025: 1 CFU Gram-positive rods identified as Streptomyces olivaceous recovered in Hood <Redacted B4>

u D '~ • 8/5/2025: 1 CFU identified as fungus Penicillium oxalicum recovered post-batch in Hood <Redacted B4> ...

Read the full 483 (PDF on fda.gov)

Observation 2

Lack of adequate personnel sampling.

Specifically,

Personnel monitoring for your operators is performed during the <Redacted B4> gowning qualification. After that personnel monitoring is performed during the <Redacted B4> gowning competency assessment and <Redacted B4> media fill qualifications. No routine personnel monitoring is performed upon completion of production batches.

Colonies belonging to human flora were isolated from ISO 5 Hoods during production:

• Hood <Redacted B4> Streptomyces olivaceous, during production of Tirzepatide Lot# 12246565 on 7/10/2025

• Hood <Redacted B4> Micrococcus luteus during production of Tirzepatide Lot #s 14031295 and 14162530 on 12/8/25.. <Redacted B4> and 12/18/25.

• Hood <Redacted B4> Micrococcus luteus during media fill on 3/24/2025

• Hood <Redacted B4> Micrococcus luteus during production of Semaglutide Lot# 14427530 on 1/12/26

• Hood <Redacted B4> Corynebacterium ureiceler during production of NAD+ Lot# 12231180 on 7/9/2025. - All the recovered isolates were not identified. However, after Gram staining, the firm categorized rest of the unidentified colonies to be of human origin. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Smoke studies were not performed under dynamic conditions.

Specifically,

Your firm conducted smoke studies on 2/9/2026 only under static conditions in Hoods <Redacted B4> and <Redacted B4> located in positive pressure clean room. These two ISO Class 5 primary engineering controls are used to compound injectable sterile drug products. The review of smoke studies performed in these hoods, in static conditions, showed empty hoods with single stream of smoke introduced towards the HEPA filter face.

Your smoke studies under static conditions only do not provide an assurance that the first air from HEPA filters is maintained over critical sites (e.g <Redacted B4> bag filled with compounded drug <Redacted B4> tubing, vials, vial stoppers) when operators position their hands and arms in the hood or when equipment and materials are arranged as during actual production, thereby creating conditions whereby sterile drug products may become contaminated. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Sterile drugs and Materials were exposed to lower than ISO 5 quality air.

Specifically,

Your firm transfers <Redacted B4> vials filled with drug products intended to be sterile from ISO Class 5 Biological Safety Cabinets (BSCs) through the ISO Class 7 negative pressure cleanroom to <Redacted B4>. During this transfer, the <Redacted B4> vials, which contain exposed sterile product, are subjected to air quality worse than ISO Class 5.

Your firm also operates <Redacted B4> and <Redacted B4> located in the positive pressure cleanroom. <Redacted B4> vials are similarly transferred from ISO Class 5 hoods through the ISO Class 7 positive pressure cleanroom to these <Redacted B4>, exposing sterile products to worse than ISO Class 5 air quality during this transfer. On 03/09/2026, I observed <Redacted B4> of vials of HCG 12,000 IU Vial Lot # 15120575 Hood <Redacted B4> to <Redacted B4>. The vials were carried in approximately <Redacted B4> trays, <Redacted B4> at a time, <Redacted B4> trays containing approximately <Redacted B4> vials and the <Redacted B4> tray was <Redacted B4> filled. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Use of <Redacted B4> that are not sterilized by routine sterilization cycles and protected from contamination by sterilizing <Redacted B4> on vacuum break air lines/vents.

Specifically,

On 3/10/26, your Production Manager stated that all of the <Redacted B4> are cleaned after each production run using <Redacted B4> with a contact time of <Redacted B4>, followed by <Redacted B4>, <Redacted B4> sterilization is conducted <Redacted B4>.

Your firm does not use <Redacted B4> sterilization, <Redacted B4> sterilization, or any other validated sterilization method to sterilize the interior chambers of the <Redacted B4> between production runs or on a routine basis.

THIS IS A REPEAT OBSERVATION.

Inspection Jan 27, 2025 to Feb 7, 2025: 7 observations

Firm on the cover
Revive Rx LLC dba Revive Rx Pharmacy, 3831 Golf Dr Ste A, Houston, TX 77018-5218
FEI number
3016710945
Establishment type on the cover
Producer of Sterile and Non-Sterile Drug Products
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Sterile drugs and Materials were exposed to lower than ISO 5 quality air.

Specifically,

A. Your firm's drug product, Trimix Gel (300 mcg / 100 mcg / 1000 mcg per ml), is prepared with nonsterile <Redacted B4> that is <Redacted B4> to be sterilized uncapped <Redacted B4> staged in an unclassified area. After the sterilization cycle, the opened and uncapped syringe is then capped using a 'sterile' cap before it is transfened into ISO 8/7 areas and ultimately, into a ISO 5 BSC for further processing. On 12/05/2024, your firm prepared□ syringes units of Trimix Gel (300 mcg/ 100 mcg/ 1000 mcg per ml) for Intraurethral Insertion, Lot 10099621 BUD:03/05/2025, with an uncapped <Redacted B4> Ithat was processed using <Redacted B4> an unclassified area. There is no assurance that the unclassified area where the non-sterile <Redacted B4> is sterilized and use of a 'sterile cap' are not rendered unsterile when exposed in an uncontrolled environment that is less than ISO 5 critical air.

B. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Microbial contamination was present in the ISO 5 area and areas adjacent to production areas.

Specifically,

A. Your firm fails to add additional routine environmental monitoring to the ISO 5 and ISO 7 critical areas to ensure that the processing conditions are free of mold, yeast, and other spore forming microorganisms found in your ISO 7 cleanroom areas and during routine personnel gowning qualifications.

i. On 01/24/2024, a recovery of Too Numerous To Count (TNTC) CFU of a gram­positive, spore forming bacteria, Paenibacillus glucanolyticus, was recovered in the ISO 7 prep cleanroom used to prepare and mix solutions;

ii. On 11/23/2023, a 3CFU recovery of mold, Penicillium sumatrense, was recovered in the ISO 7 preparation <Redacted B4> hood used to prepare and mix solutions;

iii. On 08/01/2023, there were three separate recoveries inside the ISO 7 negative pressure clean room used in the processing of drug products intended to be sterile, 1 CFU of a unknown species of Streptococcus, 2CFU of mold microorganism, Penicillium ciltrinum, and 3 CFU of another mold species, Penicillium sumatrense.

iv. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Lack of and Inadequate routine environmental monitoring in the ISO 5 area and classified areas.

Specifically, your fnm does not perform an environmental monitoring surface sample when performing aseptic processing directly in within 6 inches of the work area that the process is being performed. On 01/27/2025, the firm's quality technician was observed to take a sample of the work bench approximately a foot away from the direct area drug product pmported to be sterile was filled in. Furthermore, when placing the media plate inside the ISO 5 BSC a copious amount of sterile <Redacted B4> was directly sprayed on the closed media plate which was then placed directly on the work surface which was directly sampled once opened and applied to the work bench area during the production of Semaglutide 5mg/ml 2cc, Lot 10453555 BUD 4/27/2025.

Observation 4

Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.

Specifically, your firm's media fill program is deficient in that your media fills are not representative of the batch size, container type, and equipment used for all drug products produced intending to be sterile.

A. Your firm does not have a media fill for syringe drug products produced. For example, your firm prepares <Redacted B4> syringes <Redacted B4> syringe for Trimix Gel (300 mcg / 100 mcg I l000 mcg per ml) for Intrauret ·a Insertion without having conducted the appropriate media fill to demonstrate and assess aseptic processing when filling a syringe product inside of the ISO 5 environment.

B. Your firm does not include interventions such as loading and unloading the <Redacted B4> in your media fill program. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Smoke studies were not performed under dynamic conditions.

Specifically, your smoke studies conducted August 22, 2024, during the cleanroom recertification, are inadequate. For example, your firm's smoke studies do not consist of dynamic behaviors performed to assess complex interventions within the ISO 5 biosafety cabinet hoods class <Redacted B4>

This is a repeat OBSERVATION.

Observation 6

Failure to appropriately and regularly clean and disinfect or sterilize equipment located in the ISO 5 area.

Specifically, your firm has not established a process for <Redacted B4> cleaning of the metal diffuser covering the HEPA filters within the <Redacted B4> biosafety cabinet (BSC) class <Redacted B4> used to practice drug products purported to be sterile. Your firm produces approximately <Redacted B4> lots <Redacted B4> across the <Redacted B4> BSCs located in your clean room suites. For example, on 01/27/2025, your operator made two different drug products in the <Redacted B4> ISO 5 BSC hood <Redacted B4> with only a sanitization to the back, top bar, side walls, and work smface area of the BSC, missing the front metal diffuser before producing the second drug product made in the same OC <Redacted B4> BSC. Your firm failed to adequately clean the BSC to prevent potential cross contamination. Two drugs were observed were Semaglutide 5mg/ml 2cc, Lot 10453555 BUD 4/27/2025, and Semorelin 15mg, Lot 10453561 BUD 7/26/2025.

Observation 7

Use of lyophilizers that are not sterilized by routine sterilization cycles and protected from contamination by sterilizing filters on vacuum break air lines/vents.

Specifically, your firm does not use the sterilization cycle on the following <Redacted B4> units within your clean room areas to protect them from contamination. Furthermore, the <Redacted B4> units are not monitored using meaningful environmental monitoring data to include surface, viable active air, or non-viable air samples inside the <Redacted B4> units.

Linked 483s whose text is not shown

State board of pharmacy records

The Texas State Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatusPrior disciplinary orders (file flag)
32011Community Sterile CompoundingREVIVE RXHOUSTONActiveYes

What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 7213OSPRevive Rx PharmacyHouston, TXActive
OSP 6854OSPRevive RxHouston, TXExpired

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054021433LICENSED PHARMACYREVIVE RX LLCHOUSTON, TXACTIVE

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0003752NONRESIDENT PHARMACYREVIVE RXHOUSTON, TXACTIVE (CURRENT)

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0002513Non Resident PharmacyRevive Rx LLCHOUSTON, TXActive

Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).

LicenseType as the board gives itName on the board recordLocationStatus
5301012456PharmacyRevive Rx, LLCHouston, TXActive

GLP-1 warning letters

FDA’s posted warning letters that name a GLP-1 drug include 0 letters to Revive Rx LLC dba Revive Rx Pharmacy. See the Revive Rx LLC dba Revive Rx Pharmacy record page for those letters and any recalls.

No FDA warning letters in this index.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.